Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinson's Disease and Amyotrophic Lateral SclerosisMOLECULESIF4.62021-12-1614OAAI
Neuroprotection with the Cannabidiol Quinone Derivative VCE-004.8 (EHP-101) against 6-Hydroxydopamine in Cell and Murine Models of Parkinson's DiseaseMOLECULESIF4.62021-05-2818OAAI
Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's diseaseNEUROBIOLOGY OF DISEASEIF5.62020-07-0127OAAI
Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson's DiseaseMOLECULESIF4.62019-07-2530OAAI
Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: possible involvement of different binding sites at the PPARγ receptorJOURNAL OF NEUROINFLAMMATIONIF10.12018-01-1652OAAI